Prosecution Insights
Last updated: April 19, 2026

Examiner: PERREIRA, MELISSA JEAN

Tech Center 1600 • Art Units: 1618

This examiner grants 52% of resolved cases

Performance Statistics

51.9%
Allow Rate
-8.1% vs TC avg
865
Total Applications
+25.7%
Interview Lift
1318
Avg Prosecution Days
Based on 824 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%
§101 Eligibility
14.9%
§102 Novelty
53.8%
§103 Obviousness
16.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19240908 METHOD OF TREATING PROSTATE CANCER Final Rejection Novartis AG
18080346 METHODS AND MATERIALS FOR TREATING HYPOCAPNIA Final Rejection Mayo Foundation for Medical Education and Research
18062577 HEMOSTATIC MATERIAL COMPOSITION Non-Final OA FUJIFILM CORPORATION
19280749 COMPOSITIONS USING IRON EXCIPIENTS AND THEIR USES INCLUDING FOR THE TREATMENT OF CANCER Final Rejection Zetagen Therapeutics, Inc.
18641097 TARGETING LIGANDS FOR DISEASE-TARGETED IMAGING AGENTS AND METHODS OF USE THEREFOR Non-Final OA Curadel Surgical Innovations, Inc.
17040967 METHODS AND ASSAYS FOR MODULATING GENE TRANSCRIPTION BY MODULATING CONDENSATES Non-Final OA Massachusetts Institute of Technology
19231931 Stable, concentrated radionuclide complex solutions Non-Final OA Advanced Accelerator Applications SA
19210753 METHODS FOR TREATING PROSTATE CANCER WITH RADIOPHARMACEUTICALS Final Rejection ARTBIO, Inc.
19202402 MYOCARDITIS-TARGETED RADIONUCLIDE MOLECULAR PROBE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Non-Final OA Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
19172114 IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) Final Rejection The Johns Hopkins University
18990863 IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) Non-Final OA The Johns Hopkins University
16608021 METHODS AND AGENTS FOR THE DETECTION AND TREATMENT OF CANCER Non-Final OA CASE WESTERN RESERVE UNIVERSITY
18969629 Stable Soft Chews, and Methods to Produce Same Non-Final OA Florida Research Group, LLC
17605846 Implantable Device Coated by a Self-Assembled Monolayer and Therapeutic Agent Non-Final OA Duquesne University of the Holy Spirit
17479395 FORMULATION OF ACOUSTICALLY ACTIVATABLE PARTICLES HAVING LOW VAPORIZATION ENERGY AND METHODS FOR USING SAME Non-Final OA The Regents of the University of Colorado, a body corporate
17052928 TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD Non-Final OA Tagworks Pharmaceuticals B.V.
17522249 SUBSTITUTED ORGANOFLUOROBORATES AS IMAGING AGENTS Non-Final OA THE UNIVERSITY OF BRITISH COLUMBIA
17611560 METHODS OF CHARACTERIZING AND UTILIZING AGENT-CONDENSATE INTERACTIONS Non-Final OA Whitehead Institute for Biomedical Research
18477504 HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF Non-Final OA University of Basel
18320890 METHODS FOR MAKING ULTRASOUND CONTRAST AGENTS Non-Final OA Lantheus Medical Imaging, Inc.
18015114 COATED SUBSTRATES AND METHOD OF MAKING SAME Final Rejection Cotex Technologies Inc.
17553462 RADIOLABELED COMPOUNDS AND USES THEREOF Non-Final OA The Research Foundation for Mental Hygiene, Inc.
17696315 FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO Non-Final OA Starlight
17477419 COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY Final Rejection Rakuten Medical, Inc.
17515080 NOVEL TRICARBOCYANINE-CYCLODEXTRIN(S) CONJUGATES AND USE THEREOF Non-Final OA CYANAGEN S.R.L.
17511642 Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy Non-Final OA Wisconsin Alumni Research Foudation
17490389 PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS Final Rejection SOMSCAN APS
17048072 ANTIBODIES FOR CHELATED RADIONUCLIDES AND CLEARING AGENTS Non-Final OA Orano Med SAS

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month